The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

The purpose of the study is to evaluate the effectiveness and safety of the CBD oral solution over a period of 12 weeks. Participants will be randomly assigned to receive either the CBD solution or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will follow a 2×2 crossover design, meaning that participants will switch treatments halfway through the study. This allows researchers to compare the effects of both treatments within the same group of participants. The main goal is to see if there is a significant reduction in joint pain, as measured by a tool called the Brief Pain Inventory.

Throughout the study, participants will be monitored for any changes in their joint pain, as well as other factors such as stiffness and overall joint function. The study will also assess the impact of the treatment on participants’ quality of life, anxiety, and depression levels. Safety will be closely monitored, with attention to any side effects that may occur. The study aims to provide valuable information on whether CBD can be a helpful treatment for joint pain in patients undergoing AI therapy for early breast cancer.

The purpose of this study is to find out if GDC-4198 is safe when given alone or together with giredestrant, and to compare how well GDC-4198 combined with giredestrant works against cancer compared to abemaciclib combined with giredestrant. The study will also look at how the body processes these medicines and how they affect the cancer. The study is divided into two stages. In the first stage, a small number of participants will receive GDC-4198 either alone or with giredestrant to check for safety and to understand how the body handles the medicine. In the second stage, a larger number of participants will be randomly assigned to receive either one of two different doses of GDC-4198 combined with giredestrant, or abemaciclib combined with giredestrant. Throughout the study, doctors will monitor participants closely with regular check-ups, blood tests, and scans to see how the cancer responds to treatment and to watch for any side effects.

During the study, doctors will measure several things to understand how well the treatments work and how safe they are. They will check how long it takes before the cancer starts growing again, whether the cancer shrinks or disappears, and how long any improvement lasts. They will also track any unwanted effects from the medicines, changes in vital signs like blood pressure and heart rate, and results from blood tests. The study will also measure the levels of the medicines in the blood at different times to understand how the body processes them. Some participants will receive GDC-4198 with and without food to see if eating affects how the medicine works. The study will continue for several years to gather enough information about the long-term effects of these treatments.

The purpose of this research is to determine how well patritumab deruxtecan works compared to standard treatments in controlling the disease and helping patients live longer. The study is designed for patients whose cancer has continued to grow despite previous treatment with hormone therapy and special medications called CDK4/6 inhibitors.

During the study, participants will be randomly assigned to receive either patritumab deruxtecan or one of the standard treatment options. All medications will be given through an intravenous infusion (directly into a vein), except for capecitabine which is taken as tablets by mouth. The treatment will continue as long as it is helping the patient and side effects are manageable.

Participants may receive elacestrant, which is a type of medication used to block the effects of hormones that help cancer grow. Some individuals might also be given ribociclib, a medication known as a CDK4/6 inhibitor that helps stop cancer cells from dividing. The treatments are administered as oral use tablets. Depending on the group assigned, some participants may receive these medications alone or in combination with other standard hormone therapies, and some may receive a placebo.

The study follows participants over a period of time to monitor how they respond to the different medication combinations. The process involves tracking long-term outcomes, such as overall survival, which is the length of time from the initial diagnosis until death, and disease-free survival, which measures the time during and after treatment that a person lives without any signs or symptoms of the cancer. The researchers will also look at how the treatments affect the quality of life and any side effects that may occur during the study period.

The purpose of this study is to find out how long patients can live without their cancer getting worse when treated with this combination of medications, and to compare this with information from previous patients who received different treatments. The study will also look at how safe these medications are when used together and how well they work in shrinking tumors. Patients in this study will take both medications by mouth in the form of tablets and will continue treatment for up to 27 months or until their cancer worsens or side effects become too difficult to manage.

During the study, patients will have regular check-ups where doctors will use scans such as computerized tomography or magnetic resonance imaging to see how the cancer is responding to treatment. The study will also collect tissue samples from tumors to look for specific changes in genes, including ESR1 mutations, which might affect how well the treatment works. Patients will be asked to complete questionnaires about their quality of life and any symptoms they experience. The study is designed for patients whose cancer has spread or come back after previous hormone therapy treatment and who meet specific requirements regarding their overall health and organ function.

The purpose of this study is to evaluate the safety and effectiveness of the combination of capivasertib and fulvestrant in patients whose cancer has progressed despite previous hormone-based treatments. Participants in the study will receive these medications and will be monitored to assess how long they can continue the treatment before needing to switch to another therapy. The study will also look at how this treatment affects the quality of life of the participants.

Throughout the study, participants will take the medications orally and will be regularly assessed by healthcare professionals. The study aims to provide insights into how well this combination of treatments works in managing advanced breast cancer and improving the time patients can stay on treatment. The trial will also explore the impact of the treatment on patients’ daily lives and overall well-being.

Participants in the study will be divided into two groups, or “arms,” to receive different treatment plans. The study will last for about four months, during which the quality of life of the participants will be assessed using a specific test called the FACT-B quality of life test. This test helps to measure how the treatment impacts the daily life and well-being of the participants. The study will also look at other factors, such as the response rate to the treatment, the safety and side effects of the medications, and how the body processes the medication over time.

The trial aims to determine if there is a significant improvement in the quality of life for patients taking everolimus, and whether it is possible to safely increase the dose for some patients. The study will also monitor the occurrence and severity of any side effects experienced by participants. By the end of the study, researchers hope to gather valuable information that could help improve treatment options for people with metastatic breast cancer.

The purpose of the study is to understand how these medications, when used around the time of surgery, affect inflammation and neurotransmitter levels in the body. Participants will receive either ketorolac, pregabalin, or a placebo before their surgery. The study will monitor changes in inflammation and neurotransmitter levels in the blood, as well as other factors related to the cancer and the body’s response to surgery.

Throughout the study, participants will have their blood tested at various times to measure changes in specific substances. The study will also look at how these medications might affect anxiety and pain levels after surgery. The goal is to gather information that could help improve treatment strategies for breast cancer patients in the future.

Participants in the study will be randomly assigned to one of two groups. One group will receive the standard hormone therapy alone, while the other group will receive both the standard hormone therapy and Palbociclib. The treatment with Palbociclib will last for two years, while the hormone therapy will continue for at least five years. The study will monitor participants over time to see how well they do with each treatment approach, focusing on how long they remain free from invasive breast cancer.

The trial aims to provide valuable information about the potential benefits of combining Palbociclib with hormone therapy for patients with HR+/HER2- early breast cancer. By comparing the two treatment groups, researchers hope to learn more about the effectiveness and safety of this combination therapy. The study is expected to continue until the end of 2028, allowing for a comprehensive evaluation of the long-term outcomes for participants.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

Participants in the study will take part in a treatment period that can last up to 24 months. During this time, they will receive either the combination of endocrine therapy and ribociclib or chemotherapy. The study aims to observe the participants over a period of time to see how well the treatments work in preventing the cancer from coming back and to monitor the overall health and quality of life of the participants.

The study will also look at how well participants adhere to their treatment plans, which means how consistently they take their medication as prescribed. Additionally, researchers will collect information on the participants’ response to treatment, including any changes in the size of the tumor and the rate of breast-conserving surgeries. The ultimate goal is to find the most effective treatment option for patients with HR-positive/HER2-negative early breast cancer, improving their chances of living without the disease returning.

Participants in the study will receive one of three different treatment plans. The first plan involves taking neratinib along with loperamide from the start. The second plan includes starting with a lower dose of neratinib and increasing it gradually, with loperamide given as needed. The third plan combines neratinib with both loperamide and colesevelam. The purpose of these different approaches is to find the best way to reduce the number of patients who stop taking neratinib due to diarrhea.

The study will last for a maximum of 12 months, during which participants will be monitored for any side effects and how they respond to the treatment. The goal is to improve the management of side effects so that patients can continue their cancer treatment with fewer interruptions. This research is important for finding better ways to support patients with HER2-positive, hormone receptor-positive early-stage breast cancer in their treatment journey.

Participants in the study will receive either the combination of Capivasertib and Fulvestrant or a placebo with Fulvestrant. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The trial will monitor the participants over time to assess the progression of the disease and any side effects that may occur. The study will also look at specific genetic changes, such as PIK3CA mutations, to see if they affect how well the treatment works.

The trial aims to provide valuable information on the safety and effectiveness of Capivasertib and Fulvestrant in treating this type of breast cancer. It will also gather data on overall survival rates, response to treatment, and quality of life for participants. The study is expected to continue until 2025, allowing researchers to collect comprehensive data on the long-term effects of the treatment. Participants will be closely monitored throughout the study to ensure their safety and well-being.

Participants in the study will receive palbociclib for two years as part of their treatment plan. The study will compare the outcomes of patients receiving this treatment with those receiving standard chemotherapy. The trial will monitor the patients over several years to assess the effectiveness of the treatment in preventing cancer recurrence and to evaluate the overall survival rates. The study will also track any side effects experienced by the participants and how these might affect their quality of life.

The trial is designed for patients who have undergone surgery for their breast cancer and are at high risk of the cancer returning. It is specifically targeting older patients, as they may have different treatment needs compared to younger individuals. The study will help determine if palbociclib can offer a viable alternative to chemotherapy, potentially providing a treatment option with fewer side effects for this group of patients.

The purpose of the study is to evaluate how well DB-1303 works in slowing down the progression of the cancer compared to the usual chemotherapy treatments. Participants in the study will be randomly assigned to receive either DB-1303 or one of the standard chemotherapy drugs, which may include Capecitabine, Paclitaxel, or Paclitaxel Albumin-Bound. These chemotherapy drugs are commonly used to treat breast cancer and are administered either orally or through intravenous infusion, depending on the specific medication.

The study will take place over a period of time, during which participants will receive their assigned treatment and be monitored for any changes in their condition. The goal is to determine which treatment is more effective in extending the time before the cancer progresses. Participants will also be observed for any side effects or changes in their overall health. This study aims to provide valuable information that could help improve treatment options for patients with this specific type of breast cancer.

The purpose of the study is to evaluate the safety of OP-1250 and to see how well it works compared to the standard treatments. Participants in the study will receive either OP-1250 or one of the standard treatments. OP-1250 is taken as a tablet by mouth, while some of the standard treatments are given as injections. The study will last for a period of up to 42 days, during which the effects of the treatments will be monitored.

Throughout the study, doctors will closely observe participants to ensure their safety and to gather information on how the treatments affect the cancer. This includes checking for any side effects and measuring how the cancer responds to the treatment. The information collected will help determine if OP-1250 could be a better option for treating this type of breast cancer in the future.

The main purpose is to determine if using palbociclib together with hormone therapy for 3 years can help prevent the cancer from returning compared to using only hormone therapy. Palbociclib belongs to a group of drugs called CDK4/6 inhibitors, which work by blocking certain proteins that help cancer cells grow.

During the study, patients will receive either palbociclib tablets or capsules (at doses of 75 mg, 100 mg, or 125 mg) along with their regular hormone therapy, or they will receive only hormone therapy. The treatment will continue for up to three years, and doctors will monitor how well the treatment works and check for any side effects.

The purpose of the study is to find out which of these two medications is more effective in reducing hot flashes. Participants will receive both treatments at different times during the study, allowing researchers to compare the effects within the same individual. This approach is known as a “cross-over” study. The study will last for several weeks, during which participants will take one medication for a period, then switch to the other. Throughout the study, participants will keep a daily record of their hot flashes in a Hot Flash Diary.

In addition to tracking hot flashes, the study will also look at other factors such as any side effects, sleep quality, overall quality of life, and mental health aspects like anxiety and depression. The study aims to provide valuable information that could help improve the quality of life for women dealing with hot flashes after breast cancer treatment.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

Participants in the study will receive either MK-2870 alone, MK-2870 with pembrolizumab, or a chemotherapy treatment selected by their physician. The study will last for a period of up to 12 months, during which the effects of the treatments will be monitored. The study aims to determine which treatment option is more effective in managing the cancer and improving the quality of life for participants.

The trial will involve regular check-ups and assessments to track the progress of the disease and any side effects experienced by participants. The study will help researchers understand the potential benefits and risks of using MK-2870 and pembrolizumab in treating this type of breast cancer, providing valuable information for future treatment options.

The purpose of the study is to see how well the new treatment works in slowing down the progression of the cancer and to assess its safety. Participants will be randomly assigned to receive either the new treatment combination or the standard hormone therapy with Everolimus. The study will last for a period of up to 42 days, during which participants will take the medications orally. The study will also involve regular check-ups and monitoring to track the progress of the disease and any side effects that may occur.

By participating in this study, researchers aim to gather important information that could help improve treatment options for patients with this type of breast cancer. The study will focus on patients who have previously been treated with a type of medication called a CDK4/6 inhibitor and hormone therapy. The results will help determine if the new treatment combination is more effective than the current standard options available for managing this condition.

Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how they respond. The study will look at the frequency and severity of diarrhea and neutropenia, as well as other potential side effects. The study will also explore how the treatment affects the size of the cancer and how long it takes for the cancer to respond to the treatment. Additionally, researchers will investigate the relationship between certain biological markers and the effectiveness of the treatment, as well as changes in the gut microbiome, which is the community of microorganisms living in the digestive tract.

The trial is designed to gather information that could help improve the management of side effects in patients with these types of breast cancer, potentially leading to better treatment outcomes. The study is expected to continue until early 2026, with the goal of providing valuable insights into the treatment of advanced breast cancer.

The purpose of the study is to find out how well 68Ga-FAPI-46 works compared to 18F-FDG in detecting cancer in patients with ER-positive breast cancer, which means the cancer cells grow in response to the hormone estrogen. The study will involve patients undergoing PET scans with both tracers to see which one provides more accurate information about the cancer.

Participants in the study will receive injections of the tracers and then have PET scans performed. The study will look at how many cancer spots are detected by each tracer and whether one tracer finds more spots than the other. This information will help doctors understand which tracer might be better for imaging hormone-positive breast cancer in the future.

The main purpose of this study is to determine if adding ribociclib to standard hormone therapy improves outcomes for patients with early breast cancer compared to hormone therapy alone. Ribociclib is given as a tablet that is taken by mouth, while goserelin is given as an injection under the skin. Anastrozole and letrozole are also taken as tablets.

During the study, patients will receive either the combination of ribociclib with hormone therapy or hormone therapy by itself. The treatment continues for up to 5 years, and patients will have regular check-ups to monitor their health. The study team will track how long patients remain free from cancer returning and assess the overall safety of the treatment combination.

Participants in the study will be randomly assigned to either continue or discontinue the CDK4/6 inhibitors while continuing with endocrine therapy. The study will monitor the patients over a period to see if the cancer remains stable without the CDK4/6 inhibitors. The main focus is to observe the progression-free survival rate, which means the length of time during and after the treatment that the patient lives with the disease without it getting worse. This will be assessed through imaging tests to check for any signs of cancer progression.

The trial aims to provide insights into the long-term management of metastatic HR-positive, HER2-negative breast cancer by understanding the effects of discontinuing CDK4/6 inhibitors. This could potentially lead to new strategies for maintaining disease control while minimizing medication use. The study is expected to run until 2028, with recruitment starting in late 2023.

The purpose of this study is to determine if a combination of Giredestrant and Triptorelin is more effective in reducing cancer cell growth compared to a combination of Anastrozole and Triptorelin. Additionally, the study will assess if Giredestrant alone can provide similar benefits as when it is combined with Triptorelin. Participants will receive these treatments over a period of four weeks. The study will involve taking medication either orally or through an injection, depending on the specific treatment being tested.

Throughout the study, participants will undergo regular monitoring to assess the effects of the treatments on their cancer. This will include taking samples from the tumor before and after the treatment period to evaluate changes in cancer cell activity. The study aims to provide valuable insights into the effectiveness of these hormone therapies in managing ER-positive/HER2-negative early breast cancer in premenopausal women.

Participants in the study will be randomly assigned to one of two groups. One group will receive the combination of abemaciclib and standard hormone therapy, while the other group will receive only the standard hormone therapy. The study will be conducted in an open-label manner, meaning that both the participants and the researchers will know which treatment each participant is receiving. The treatment period will last up to 24 months, during which participants will take the medication orally in the form of film-coated tablets. Throughout the study, participants will be monitored regularly to assess their health and the effectiveness of the treatment.

The main goal of the study is to determine if the combination of abemaciclib and standard hormone therapy can improve the time participants remain free from invasive breast cancer compared to those receiving only the standard hormone therapy. Additionally, the study will look at other outcomes, such as overall survival and quality of life, to provide a comprehensive understanding of the treatment’s impact. Participants will be followed for several years to gather long-term data on the effectiveness and safety of the treatment.

The purpose of the study is to understand how much time healthcare providers and patients can save when using the new injection method compared to the traditional infusion method. Participants in the study will receive the treatment over several cycles, and the time taken for each method will be measured. This includes the time spent by healthcare providers in preparing and administering the treatment, as well as the time patients spend in the treatment chair and in the hospital.

The study will also look at the safety and tolerability of the new injection method compared to the traditional infusion method. This means checking for any side effects or reactions that might occur with the new treatment. The study aims to provide valuable information on whether the new method can make the treatment process more efficient and comfortable for patients with .

The treatment being tested is an oral solution containing cannabidiol, also known as CBD. CBD is a compound derived from the cannabis plant, and it is being studied for its potential to relieve joint pain associated with aromatase inhibitors. The study will compare the effects of CBD with a placebo over a period of 12 weeks to see if it can help reduce the pain experienced by patients. The goal is to determine if CBD can effectively alleviate the musculoskeletal symptoms that some patients experience during their cancer treatment.

Participants in the study will receive either the CBD oral solution or a placebo in a randomized and double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure the results are unbiased. The study will monitor the participants’ joint pain and overall well-being throughout the trial period, using various assessments to gather data on the treatment’s safety and effectiveness. The study aims to provide valuable insights into whether CBD can be a beneficial addition to the treatment plan for patients experiencing joint pain due to their cancer therapy.

The purpose of the study is to evaluate how well these treatments work in patients whose cancer has become resistant to previous hormone therapy. Participants will be randomly assigned to receive either Giredestrant or Fulvestrant, along with a CDK4/6 inhibitor. The study will monitor the participants over a period of time to assess the progression of the disease and any side effects experienced. The trial aims to provide insights into which treatment combination might be more effective in managing this type of breast cancer.

Throughout the study, participants will receive regular check-ups and assessments to track their health and the cancer’s response to the treatment. The trial will also gather information on the overall survival of participants and any changes in their quality of life. This research is important for understanding better treatment options for patients with advanced breast cancer that is resistant to standard hormone therapies.

The purpose of this study is to compare the effectiveness and safety of giredestrant combined with Phesgo versus Phesgo alone. The study will first give all participants an induction treatment phase consisting of Phesgo combined with a taxane chemotherapy. After this initial treatment phase, participants will be randomly assigned to receive either Phesgo combined with giredestrant or Phesgo alone. The study will measure how long participants live without their cancer getting worse, as well as overall survival time, how well the cancer responds to treatment, and the duration of that response.

During the study, participants will be monitored for side effects and changes in their health status. The study will also assess quality of life and how well participants are able to function in their daily activities using standardized questionnaires. Blood tests and other clinical assessments will be performed regularly to monitor safety throughout the treatment period.

The purpose of the study is to estimate the survival rates of patients, focusing on how long they live without the cancer getting worse and their overall survival at 12 months. Participants will receive treatment for up to 48 months, during which they will take Ribociclib and one of the other medications mentioned. Some participants may receive a placebo instead of one of the medications to help compare the effects. The study will monitor the participants’ health and any side effects they experience during this period.

Throughout the study, participants will have regular check-ups and tests to track their progress and the effectiveness of the treatment. The study will also assess the quality of life of the participants using a questionnaire called FACT-G/FACT-B, which is designed to measure health-related quality of life in cancer patients. The ultimate goal is to gather comprehensive data on how Ribociclib and the other medications work together in treating advanced breast cancer, providing valuable insights for future treatments.

The main purpose of this research is to determine how well inavolisib combined with fulvestrant works compared to alpelisib combined with fulvestrant in treating this specific type of breast cancer. The study will measure how long patients live without their cancer getting worse. Other aspects being studied include overall survival time, how well tumors respond to treatment, and how the treatments affect patients’ quality of life.

Participants will receive either inavolisib or alpelisib pills taken by mouth daily, along with fulvestrant given as an intramuscular injection. During the study, patients will have regular medical check-ups and tests to monitor their cancer and any side effects from the treatment. The effectiveness of the treatment will be assessed through various medical examinations and imaging tests.

The purpose of this study is to evaluate the biological activity of Elacestrant, with or without the addition of Triptorelin, in women who have estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer that can be surgically removed. The study will look at how these treatments affect the estrogen receptor pathway and the proliferation of cancer cells, as measured by a marker called Ki67. Participants will be randomly assigned to receive either Elacestrant alone or in combination with Triptorelin, and the effects will be monitored over a short period before surgery.

Throughout the study, participants will undergo various assessments to measure changes in cancer cell activity and hormone levels. The trial aims to provide insights into how these treatments can impact the growth of breast cancer cells and potentially improve outcomes for patients. The study is designed to be open-label, meaning both the participants and researchers will know which treatment is being administered. This trial is part of ongoing research to find effective treatments for breast cancer and to understand the role of hormone pathways in cancer progression.

The main treatment being studied is a medication called sacituzumab govitecan, which is also known by its code name IMMU-132. This medication is an antibody-drug conjugate, which means it combines an antibody with a drug to target cancer cells more precisely. The study will compare the effects of sacituzumab govitecan with other treatments chosen by the patient’s doctor, which may include medications like capecitabine, nab-paclitaxel, or paclitaxel. These are all types of chemotherapy drugs used to treat cancer.

The purpose of the study is to evaluate how well sacituzumab govitecan works compared to the other treatments in terms of delaying the progression of the disease. Patients participating in the study will receive either sacituzumab govitecan or one of the other treatments, and their health will be monitored over time to assess the effects of the treatment. The study will involve regular check-ups and assessments to track the progress of the cancer and any side effects of the treatments. The study aims to provide valuable information that could help improve treatment options for patients with this type of breast cancer in the future.

The purpose of the study is to evaluate how well these treatments work in reducing the amount of cancer left after treatment, known as the Residual Cancer Burden (RCB). Patients will be randomly assigned to one of the two treatment groups. The study will involve taking the assigned medication for a period of time before undergoing surgery to remove the breast cancer. Throughout the study, patients will have regular check-ups and tests to monitor their health and the effectiveness of the treatment. The study will also look at other factors, such as changes in a protein called Ki67, which is related to how quickly cancer cells are growing.

This trial is designed to help doctors understand which treatment option is more effective and safer for patients with this specific type of breast cancer. The study will continue for several years to gather enough information to make a clear comparison between the two treatment methods. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to see if adding these treatments can improve the response of the primary tumor and any cancer that has spread to nearby lymph nodes. Participants will be randomly assigned to different groups, each receiving a different combination of treatments. The study will monitor the response of the cancer to these treatments over time, with regular assessments to track progress. The study aims to find out if these combinations can lead to better outcomes for patients with luminal B breast cancer.

Throughout the study, participants will undergo various tests and procedures to monitor their health and the effects of the treatments. These may include imaging tests like MRI to measure the size of the tumor and check for any changes. The study will also collect tissue and blood samples to help understand how the treatments are working. The trial is expected to continue for several years, with follow-up assessments to evaluate long-term outcomes such as survival and recurrence of the cancer.

The trial is testing a combination of three treatments: durvalumab, also known by its code name MEDI4736, olaparib, and fulvestrant. Durvalumab is given as an infusion into a vein, olaparib is taken as a tablet, and fulvestrant is given as an injection. The purpose of the study is to evaluate how effective this combination is in treating the specific type of breast cancer mentioned above. The study will also look at the safety of these treatments when used together.

Participants in the study will receive the treatments over a period of time, and their health will be monitored regularly. The main goal is to see if the cancer stops growing or shrinks within 24 weeks of starting the treatment. The study will also track how long patients live without the cancer getting worse and any side effects they might experience. This information will help doctors understand if this combination of treatments could be a good option for patients with this type of breast cancer in the future.

The treatment being tested in this study is called FLUOROESTRADIOL F-18, also known by the code name EstroTep. This is a solution that is injected into the body and used in a type of imaging called Positron Emission Tomography (PET). The purpose of the study is to see how this imaging technique can help doctors make better treatment decisions for patients whose cancer has returned after the first line of treatment. The study will involve patients undergoing a PET scan with FLUOROESTRADIOL F-18 to help guide their future treatment options.

Throughout the study, patients will receive the PET scan and their doctors will use the results to decide on the best course of treatment. This may involve changes to their current treatment plan, such as adjusting hormone therapy or adding other treatments like chemotherapy or radiotherapy. The study aims to understand how this imaging technique can improve the management of metastatic breast cancer and help doctors make more informed decisions about patient care.